Table 1.
Summary of main outcomes among systemic therapies (multi-kinase inhibitors) approved for advanced HCC.
| Study | Year | Phase | N | Line of Tx | Tx | CR (%) | ORR (%) | mPFS (Months) | mOS (Months) | HR X (95%CI) |
|---|---|---|---|---|---|---|---|---|---|---|
| SHARP [3] | 2008 | III | 602 | First | Sorafenib | 0 | 2 | 5.5 | 10.7 | 0.69 (0.55–0.87) |
| Asia-Pacific [4] | 2009 | III | 271 | First | Sorafenib | 0 | 3 | 2.8 | 6.5 | 0.68 (0.50–0.93) |
| REFLECT [9] | 2018 | III | 476 | First | Sorafenib | <1 | 9 | 3.7 | 12.3 | - |
| REFLECT [9] | 2018 | III | 478 | First | Lenvatinib | 1 | 24 | 7.4 | 13.6 | 0.92 (0.79–1.06) |
| RESORCE [10] | 2017 | III | 573 | Second | Regorafenib | 1 | 11 | 3.1 | 10.6 | 0.63 (0.50–0.79) |
| CELESTIAL [11] | 2018 | III | 707 | Second | Cabozantinib | 0 | 4 | 5.2 | 10.2 | 0.76 (0.63–0.92) |
| REACH-2 [12] | 2019 | III | 542 | Second | Ramucirumab | 0 | 5 | 2.8 | 8.5 | 0.71 (0.53–0.95) |
CI: Confidence interval; CR: Complete response; HR: Hazard ratio; mOS: Median overall survival; mPFS: Median progression-free survival; N: Number of patients; ORR: Objective response rate; Tx: Treatment; X HR for mOS.